Apogee Therapeutics(APGE),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community - To The Moon

At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.

Close

APGE Apogee Therapeutics

Post-Mkt 07-02 18:42:57 EDT

132.91

+0.14

+0.11%

盘后132.91

+0.000.00%

17:39 EDT

High133.85	Low132.73	Vol3.00M
Open133.60	D1 Closing132.77	Amplitude0.84%
Mkt Cap10.01B	Tradable Cap9.34B	Total Shares75.34M
T/O398.34M	T/O Rate4.27%	Tradable Shares70.31M
P/B--	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

Loading ...

{"stockData":{"symbol":"APGE","market":"US","secType":"STK","nameCN":"Apogee Therapeutics","latestPrice":132.91,"timestamp":1783022400000,"preClose":132.77,"halted":0,"volume":2998799,"hourTrading":{"tag":"盘后","latestPrice":132.91,"preClose":132.91,"latestTime":"17:39 EDT","volume":31032,"amount":4125182.44176,"timestamp":1783028392201,"change":0,"changeRate":0,"amplitude":0.000677},"delay":0,"changeRate":0.0010544550726819789,"floatShares":70308023,"shares":75339900,"eps":-4.320623,"marketStatus":"Post-Mkt","change":0.14,"latestTime":"07-02 18:42:57 EDT","open":133.6,"high":133.85,"low":132.73,"amount":398338537.93931,"amplitude":0.008436,"askPrice":134.2,"askSize":4000,"bidPrice":132.76,"bidSize":3162,"shortable":3,"etf":0,"ttmEps":-4.320623,"tradingStatus":3,"nextMarketStatus":{"tag":"Closed","tradingStatus":0,"beginTime":1783036800000},"marketStatusCode":4,"adr":0,"listingDate":1689307200000,"exchange":"NASDAQ","adjPreClose":132.77,"preHourTrading":{"tag":"盘前","latestPrice":132.77,"preClose":132.77,"latestTime":"09:29 EDT","volume":1621,"amount":215343.75504,"timestamp":1782998999999,"change":0,"changeRate":0,"amplitude":0.010573},"postHourTrading":{"tag":"盘后","latestPrice":132.91,"preClose":132.91,"latestTime":"17:39 EDT","volume":31032,"amount":4125182.44176,"timestamp":1783028392201,"change":0,"changeRate":0,"amplitude":0.000677},"volumeRatio":0.663694,"impliedVol":0.0535,"impliedVolPercentile":0.004},"requestUrl":"/m/hq/s/APGE","defaultTab":"news","newsList":[{"id":"2648791544","title":"Oruka Therapeutics H2 ORKA-001 Data Could Further De-Risk Lead Program, UBS Says","url":"https://stock-news.laohu8.com/highlight/detail?id=2648791544","media":"MT Newswires Live","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2648791544?lang=en_us&edition=fundamental","pubTime":"2026-07-01 23:23","pubTimestamp":1782919428,"startTime":"0","endTime":"0","summary":"Oruka Therapeutics  could further de-risk its lead psoriasis drug candidate, ORKA-001, with H2 data expected to show stronger 28-week efficacy than its earlier results and AbbVie's  Skyrizi, UBS Securities said in a Wednesday note.The firm said psoriasis treatments typically show improving efficacy over time. It expects ORKA-001's PASI100 response rate to increase from about 63% at week 16 to 70% to 80% at week 28.UBS said initial one-year durability data should provide an early indication of ORKA-001's potential for six-month or annual dosing. The firm expects the update in late Q3 or Q4, giving the company more time to include one-year data from additional patients.The investment firm also said AbbVie's planned acquisition of Apogee Therapeutics  validates the underlying YTE platform used by ORKA-001 and eases concerns about the intellectual property landscape.UBS maintained its buy rating on Oruka and raised its price target to $130 from $100.Price: 94.44, Change: -0.73, Percent Cha","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["IE000SO60NU8.SGD","IE0000B7K699.USD","IE00B4R5TH58.HKD","LU1003077747.HKD","LU1670627923.USD","LU2237443895.HKD","ABBV","LU0708994859.HKD","LU0069063385.USD","LU1074936037.SGD","LU1244550221.USD","LU0310799852.SGD","SG9999003800.SGD","IE00BDGV0183.EUR","LU0098860793.USD","SG9999015978.USD","LU0158827948.USD","LU1267930573.SGD","LU1732799900.SGD","LU1934455277.USD","BK4139","LU1093756168.USD","LU0861579265.USD","LU0170899867.USD","LU0057025933.USD","BK4550","LU0965509283.SGD","LU2237443622.USD","LU0553294199.USD","ORKA","IE00B3PB1722.GBP","LU0417517546.SGD","LU0122379950.USD","LU1732800096.USD","LU0661504455.SGD","LU0985320562.USD","LU1061106388.HKD","IE00BFTCPJ56.SGD","APGE","LU0203347892.USD","LU1037948897.HKD","LU2129689605.HKD","DBB","LU1551013342.USD","LU2089984988.USD","LU0211328371.USD","LU0943347566.SGD","IE00BJJMRZ35.SGD","BK4534","LU0203345920.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2647322702","title":"Analysts’ Top Healthcare Picks: Revolution Medicines (RVMD), Apogee Therapeutics (APGE)","url":"https://stock-news.laohu8.com/highlight/detail?id=2647322702","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2647322702?lang=en_us&edition=fundamental","pubTime":"2026-06-29 16:50","pubTimestamp":1782723018,"startTime":"0","endTime":"0","summary":"There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Revolution Medicines (RVMD) and Apogee Therapeutics ...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/analysts-top-healthcare-picks-revolution-medicines-rvmd-apogee-therapeutics-apge-blurbs-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/analysts-top-healthcare-picks-revolution-medicines-rvmd-apogee-therapeutics-apge-blurbs-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["LU0053671581.USD","LU0128526141.USD","HCSG","BK4581","XLV","IE0009355771.USD","LABU","IE00BJJMRZ35.SGD","RVMD","LU0889565916.HKD","XBI","IE0002141913.USD","IE00BFTCPJ56.SGD","BK4585","IE00B2B36J28.USD","APGE","BK4139","BK4137","LU0029874061.USD","LU0109394709.USD","IE00BJT1NW94.SGD","BK4588","IE00B4R5TH58.HKD","LU0320765992.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2646736234","title":"Healthcare Stocks Have Become a Haven for Investors Ditching Tech","url":"https://stock-news.laohu8.com/highlight/detail?id=2646736234","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2646736234?lang=en_us&edition=fundamental","pubTime":"2026-06-27 10:30","pubTimestamp":1782527400,"startTime":"0","endTime":"0","summary":"AbbVie, Lilly and J&J’s shares all closed at all-time highs.","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":true,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU1032955483.USD","SG9999017495.SGD","LU1291159041.SGD","LU1778281490.HKD","LU0096364046.USD","LU1629891620.HKD","LU0320765992.SGD","LU0353189680.USD","BK4599","LU1267930730.SGD","LU1267930573.SGD","LU0689626769.HKD","LU0861579265.USD","LU1127390331.HKD","BK4585","LU0353189763.USD","LU1868837136.USD","SGXZ57979304.SGD","IE0005OL40V9.USD","LU0320765059.SGD","IE0002141913.USD","LU1934455277.USD","IE00BVYPNV92.GBP","LU0203347892.USD","IE000WAW04H5.SGD","IE00BJJMRX11.SGD","IE0001KFT4U8.USD","LU0426417589.USD","LU1074936037.SGD","LU2023250330.USD","SG9999013999.USD","LU1066051498.USD","LU1720051108.HKD","LU2430703251.USD","LU0079474960.USD","IE000F7OJYX1.SGD","LU2129689605.HKD","SG9999011175.SGD","LU2552382215.SGD","LU2168564222.USD","SGXZ81514606.USD","IE00B1XK9C88.USD","LU1585245621.USD","LU2087625088.SGD","LU0942090050.USD","LU0795875086.SGD","LU2468319806.SGD","IE00BKDWB100.SGD","IE00BWXC8680.SGD","IE00B775H168.HKD","LU1839511570.USD","LU1280957306.USD","LU1935042991.SGD","LU0133085943.USD","LU2063271972.USD","LU2237443382.USD","IE00BJLML261.HKD","LU0708995401.HKD","LU0006306889.USD","IE00BK4W5M84.HKD","LU0238689110.USD","LU1003077747.HKD","BK4504","LU1814569148.SGD","IE00B4JS1V06.HKD","LU2087621335.USD","LU2462157665.USD","LU0234572021.USD","LU2213496289.HKD","LU1037948897.HKD","LU0859254822.USD","LU0511384066.AUD","LU0553294199.USD","LU1037948541.HKD","LU1162221912.USD","LU2237443549.SGD","LU0345769128.USD","SG9999001176.SGD","IE0009355771.USD","LU1551013425.SGD","IE00BJJMRY28.SGD","LU1548497426.USD","LU1732800096.USD","LU0965509010.AUD","LU0058720904.USD","LU0823434583.USD","BK4581","LU1093756168.USD","LU0057025933.USD","LU2552382058.USD","LU0266013472.USD","LU2592432038.USD","LU2430703095.HKD","LU1934455863.HKD","LU1917777945.USD","LU2361044865.SGD","LU1066051225.USD","IE00BJJMRZ35.SGD","IE00BSNM7G36.USD","LU0738911758.USD","SG9999001440.SGD","LU1221951129.SGD","LU1069344957.HKD","LU2089284900.SGD","LU2271345857.HKD","LU0158827781.USD","LU2471134796.USD","LU0109394709.USD","IE00B19Z3B42.SGD","LU2430703178.SGD","LU0787776722.HKD","SNY","LU2133065610.SGD","LU2237443978.SGD","LU0354030438.USD","LU2360106947.USD","IE0034235303.USD","IE00B3PB1722.GBP","IE00BGHQF631.EUR","LU2211815571.USD","LU0385154629.USD","LU0124676726.USD","LU1894683264.USD","LU2456880835.USD","LU2237438978.USD","LU0786609619.USD","LU1670628061.USD","ABSI","IE000MB6IJN5.SGD","SG9999014898.SGD","LU2746668974.SGD","LU1732799900.SGD","LU2471134523.USD","IE00B1BXHZ80.USD","IE00BJT1NW94.SGD","LU0882574139.USD","BK4534","LU0889565916.HKD","LU1868837300.USD","LU1496350171.SGD","LU0545039389.USD","BK4568","LU0114720955.EUR","IE00BN29S564.USD","BK4139","IE00BFXG1179.USD","LU2111349929.HKD","IE00BKPKM429.USD","IE0004445015.USD","LU2089984988.USD","LU0943347566.SGD","BK4592","LU1868836591.USD","LU0106261372.USD","LU2236285917.USD","IE00BDGV0183.EUR","LU0472753341.HKD","LU0820561818.USD","LU1196500208.SGD","LU1989771016.USD","LU2417539215.USD","BK4588","IE000BZT7R73.USD","LU0289739343.SGD","MRNX","LU0061475181.USD","SG9999002224.SGD","LU1989772923.USD","SG9999014906.USD","LU1929549753.HKD","LU1145028129.USD","LU0225283273.USD","IE0004445239.USD","LU0426412945.USD","LU1066051811.HKD","SG9999015952.SGD","LU2168564065.EUR","LU0210536198.USD","LU2602419157.SGD","BK4516","LU1244550221.USD","IE0000B7K699.USD","SG9999014914.USD","LU2552382132.HKD","LU0471298777.SGD","IE00BVYPNW00.USD","LU0310799852.SGD","LU1043141123.HKD","LU1064131342.USD","LU0661504455.SGD","LU0109391861.USD","LU2168564149.EUR","LU0683600562.USD","IE00BLSP4452.SGD","LU0994945656.USD","GB00BDT5M118.USD","SG9999002232.USD","LU0256863811.USD","LU2756315318.SGD","SGXZ51526630.SGD","LU0345770308.USD","LU2491050071.SGD","LU2324357040.USD","SG9999014880.SGD","LU0889566641.SGD","IE00B19Z3581.USD","LU0545562505.USD","LU0094547139.USD","LU0320765646.SGD","BK4007","LU2168563687.JPY","LU1983299246.USD","LU0640476718.USD","LU1057294990.SGD","ELIS","IE00BFTCPJ56.SGD","IE00B7KXQ091.USD","IE00B4R5TH58.HKD","LU0965509101.SGD","LU0792757196.USD","LU1323610961.USD","LU2403377893.USD","LU0345770993.USD","LU0210528500.USD","LU2028103732.USD","IE00BK4W5L77.USD","LU2491049909.HKD","LU0471298694.HKD","LU1988902786.USD","LU2471134879.HKD","LU0070217475.USD","LU1093756325.SGD","IE00BFSS7M15.SGD","LU0211327993.USD","LU0097036916.USD","LU1712237335.SGD","LU2237443895.HKD","LU1718418525.SGD","LU1061106388.HKD","LU1674673428.USD","LLY","LU1244550577.SGD","LU1267930813.SGD","LU0868494617.USD","LU2112291526.USD","LU1121112475.USD","LLYZ","SG9999001176.USD","SG9999015986.USD","IE000SO60NU8.SGD","LU0949170772.SGD","LU1894683348.USD","LU0795875169.SGD","LU0158827948.USD","LU1720051017.SGD","LU2750360997.AUD","LU1934455194.USD","IE00BLSP4239.USD","LU2129689431.USD","LU0868494708.USD","LU2491050154.USD","LU1228905540.USD","LU1267930490.SGD","LU0345769631.USD","BK4559","LU0708994859.HKD","LU1066053197.SGD","LU2023251221.USD","LU0203345920.USD","IE0002270589.USD","LU0198837287.USD","LU1551013342.USD","LU0128525929.USD","LU0456855351.SGD","LU2361045086.USD","LU1804176565.USD","LU1670627923.USD","SGXZ31699556.SGD","IE00BBT3K403.USD","LU0964807845.USD","LU2106854487.HKD","LU0417517546.SGD","BK4566","BK4550","LU2750360641.GBP","LU0122379950.USD","LU0985320562.USD","LU1868836757.USD","LU0820562030.AUD","LU0289961442.SGD","SG9999015978.USD","LU1232071149.USD","IE00B3T34201.USD","LU1023059063.AUD","LU1059921491.USD","LU2168564495.EUR","ABBV","LU2023250504.SGD","SG9999018857.SGD","LU0203201768.USD","LLYX","LU0965509283.SGD","LU1261432733.SGD","LU0069063385.USD","SG9999018865.SGD","LU2357627491.SGD","XBI","SG9999015945.SGD","LU1989772840.SGD","LU2108987350.USD","LU1366192091.USD","LU2089283258.USD","MRNA","JNJ","LU1221951046.USD","IE00BKVL7J92.USD","LU0203202063.USD","LU2471134952.CNY","LU2896262040.SGD","XLV","LU2265009873.SGD","LU2756315664.SGD","BK4532","LU0029864427.USD","SG9999003800.SGD","LU0823416689.USD","LU0912757837.SGD","LU1974910355.USD","LU1623119135.USD","LU2347655156.SGD","IE00B7SZLL34.SGD","LU0098860793.USD","REGN","LU0882574055.USD","IE000M9KFDE8.USD","LU0289739699.SGD","LU0432979614.USD","LU0965508806.USD","LU2357305700.SGD","LU2129689514.USD","LU2264538146.SGD","LU1674673691.USD","LU0256863902.USD","LU1496350502.SGD","LU2487616109.SGD","LU1868836914.USD","LU0310800379.SGD","LU0234570918.USD","LU2505996509.AUD","IE00BZ1G4Q59.USD","LU1228905037.USD","LU0211328371.USD","BK4533","LU0170899867.USD","LU1244550494.USD","LU1430594728.SGD","LU0820561909.HKD","LU1043141396.HKD","LU2505996681.GBP","LU0323591593.USD","LU0316494557.USD","LU1914381329.SGD","LU0354030511.USD","APGE","LU2746668461.USD","SGXZ99366536.SGD","IE00BN8TJ469.HKD","LU1035775433.USD","LU2461242641.AUD","LU0672654240.SGD","LU0823434740.USD","LLII","MRNY","LU0466842654.USD","ELIL","IE00B42XCP33.USD","IE00BFSS8Q28.SGD","LU2237443622.USD","LU1032466523.USD","LU2361044949.HKD","IE00B2B36J28.USD","LU0689472784.USD","LU1506573853.SGD","LU2237443465.HKD","LU0053666078.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2646954842","title":"Apogee Therapeutics CEO Michael Thomas Henderson Sells 80,000 Shares for $10.6 Million","url":"https://stock-news.laohu8.com/highlight/detail?id=2646954842","media":"Reuters","labels":["shareholding","insiderTrades"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2646954842?lang=en_us&edition=fundamental","pubTime":"2026-06-25 08:01","pubTimestamp":1782345673,"startTime":"0","endTime":"0","summary":"Apogee Therapeutics CEO Michael Thomas Henderson sells 80,000 shares for $10.6 millionApogee Therapeutics CEO Michael Thomas Henderson sold 80,000 common shares on June 22, 2026 at a weighted average ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260625:nNDLbFwnkL:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":"Apogee Therapeutics CEO Michael Thomas Henderson Sells 80,000 Shares for $10.6 Million","news_tag":"shareholding,insiderTrades","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["APGE","LU0053671581.USD","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2645166798","title":"Apogee Therapeutics Cut to Neutral from Buy by Guggenheim","url":"https://stock-news.laohu8.com/highlight/detail?id=2645166798","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2645166798?lang=en_us&edition=fundamental","pubTime":"2026-06-24 21:48","pubTimestamp":1782308880,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/APGE/analyst-ratings(END) Dow Jones NewswiresJune 24, 2026 09:48 ET","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["APGE"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2645816585","title":"Apogee Therapeutics downgraded to Hold from Buy at Stifel","url":"https://stock-news.laohu8.com/highlight/detail?id=2645816585","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2645816585?lang=en_us&edition=fundamental","pubTime":"2026-06-24 21:35","pubTimestamp":1782308115,"startTime":"0","endTime":"0","summary":"Stifel downgraded Apogee Therapeutics (APGE) to Hold from Buy with a price target of $135, up from $133, after the company entered into an agreemen...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/apogee-therapeutics-downgraded-to-hold-from-buy-at-stifel-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/apogee-therapeutics-downgraded-to-hold-from-buy-at-stifel-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["APGE","SF"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2645216894","title":"Apogee Therapeutics Inc : Mizuho Cuts to Neutral from Outperform; Raises Target Price to $135 from $110","url":"https://stock-news.laohu8.com/highlight/detail?id=2645216894","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2645216894?lang=en_us&edition=fundamental","pubTime":"2026-06-24 18:36","pubTimestamp":1782297414,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260624:nFWN42W0HX:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","LU0053671581.USD","APGE"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2645489426","title":"Mizuho Downgrades Apogee Therapeutics to Neutral From Outperform, Lifts Price Target to $135 From $110 Amid AbbVie Deal","url":"https://stock-news.laohu8.com/highlight/detail?id=2645489426","media":"MT Newswires Live","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2645489426?lang=en_us&edition=fundamental","pubTime":"2026-06-24 18:35","pubTimestamp":1782297325,"startTime":"0","endTime":"0","summary":"Apogee Therapeutics (APGE) has an average rating of overweight and mean price target of $132.64, according to analysts polled by FactSet.(MT Newswires covers equity, commodity and economic research fr","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["ABBV","APGE","MFG"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2645896363","title":"Apogee Therapeutics downgraded to Neutral from Outperform at Mizuho","url":"https://stock-news.laohu8.com/highlight/detail?id=2645896363","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2645896363?lang=en_us&edition=fundamental","pubTime":"2026-06-24 17:00","pubTimestamp":1782291621,"startTime":"0","endTime":"0","summary":"Mizuho analyst Joseph Catanzaro downgraded Apogee Therapeutics (APGE) to Neutral from Outperform with a price target of $135, up from $110, after t...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/apogee-therapeutics-downgraded-to-neutral-from-outperform-at-mizuho-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/apogee-therapeutics-downgraded-to-neutral-from-outperform-at-mizuho-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["APGE","MFG"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2645867928","title":"U.S. Research Roundup-bank of America, Fedex, Jpmorgan","url":"https://stock-news.laohu8.com/highlight/detail?id=2645867928","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2645867928?lang=en_us&edition=fundamental","pubTime":"2026-06-24 14:56","pubTimestamp":1782284196,"startTime":"0","endTime":"0","summary":"U.S. RESEARCH ROUNDUP-Bank of America, FedEx, JPMorganJune 24 (Reuters)-Wall Street securities analysts revised their ratings and price targets on several U.S.-listed companies, including Bank of Amer","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260624:nL4N42W0JG:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["SPG","BAC","JPM","LU2357305700.SGD","TXG","CRC","JPO","A","BLZE","CBRS","AVTR","AOSL","LABX","CE","DOW","CELH","BRKR","EWBC","WTFC","ECL","AX","CSGP","AXP","PNC","IE00BDCRKT87.USD","ADI","APGE","CELT","CFR","BANC","BOKF","HBAN","AUB","AR","CATY","CFG","JPMO","PB","JPX","LU2237438978.USD","MTB","ALAB","DLR","TCBI","EMN","BSX","FDX","IE0004445015.USD","CCL","AXPG"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2645869005","title":"Apogee Therapeutics Inc : TD Cowen Cuts to Hold From Buy","url":"https://stock-news.laohu8.com/highlight/detail?id=2645869005","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2645869005?lang=en_us&edition=fundamental","pubTime":"2026-06-24 12:09","pubTimestamp":1782274172,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260624:nFWN42W002:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["LU0053671581.USD","BK4139","APGE"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2645852666","title":"Apogee Therapeutics downgraded to Hold from Buy at TD Cowen","url":"https://stock-news.laohu8.com/highlight/detail?id=2645852666","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2645852666?lang=en_us&edition=fundamental","pubTime":"2026-06-24 05:45","pubTimestamp":1782251111,"startTime":"0","endTime":"0","summary":"TD Cowen downgraded Apogee Therapeutics (APGE) to Hold from Buy with no price target. The firm said it is “sad to see Apogee go,” but the timing po...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/apogee-therapeutics-downgraded-to-hold-from-buy-at-td-cowen-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/apogee-therapeutics-downgraded-to-hold-from-buy-at-td-cowen-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["COWN","APGE","TD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2645854836","title":"Apogee Therapeutics (APGE) was downgraded to a Hold Rating at TD Cowen","url":"https://stock-news.laohu8.com/highlight/detail?id=2645854836","media":"TIPRANKS","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2645854836?lang=en_us&edition=fundamental","pubTime":"2026-06-24 04:55","pubTimestamp":1782248126,"startTime":"0","endTime":"0","summary":"Apogee Therapeutics received a Hold rating and price target from TD Cowen analyst Tyler Van Buren today. Van Buren covers the Healthcare sector, fo...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/apogee-therapeutics-apge-was-downgraded-to-a-hold-rating-at-td-cowen-blurbs-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/apogee-therapeutics-apge-was-downgraded-to-a-hold-rating-at-td-cowen-blurbs-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["TD","APGE","COWN"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2645370298","title":"Apogee Therapeutics' Acquisition by AbbVie Fairly Values Zumilokibart, UBS Says","url":"https://stock-news.laohu8.com/highlight/detail?id=2645370298","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2645370298?lang=en_us&edition=fundamental","pubTime":"2026-06-23 23:24","pubTimestamp":1782228290,"startTime":"0","endTime":"0","summary":"Apogee Therapeutics  proposed $10.9 billion acquisition by AbbVie  represents a \"full and fair\" valuation of its lead asset, zumilokibart, and the \"long-acting IL-13\" antibody is largely de-risked, entering Phase III development and has \"mega-blockbuster potential\" in atopic dermatitis and asthma, UBS Securities said in a note Tuesday.AbbVie's \"leading dermatology franchise\" and commercial capabilities could help maximize the value of zumilokibart, while Apogee's broader immunology portfolio further supports the \"strategic value\" of the platform. The transaction is expected to close in Q3 and is seen facing limited antitrust risk due to minimal \"overlap\" between the companies, according to the report.UBS downgraded Apogee Therapeutics to neutral from buy following the acquisition announcement, and raised the price target to $135.11 from $100, reflecting the \"implied value of the transaction,\" and noted that few significant clinical catalysts are expected for the remainder of the year.P","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["LU0310800379.SGD","LU0795875169.SGD","LU0122379950.USD","LU0158827948.USD","LU2129689514.USD","LU0795875086.SGD","LU0128525929.USD","LU0965509101.SGD","LU0820561909.HKD","LU1989772923.USD","LU0234570918.USD","LU0289739343.SGD","LU0820561818.USD","APGE","LU2357627491.SGD","BK4550","LU1093756168.USD","LU0069063385.USD","IE00B19Z3B42.SGD","LU0310799852.SGD","LU2237443895.HKD","LU0689626769.HKD","LU2468319806.SGD","LU0823416689.USD","BK4559","LU1061106388.HKD","IE000BZT7R73.USD","LU2347655156.SGD","IE00BLSP4452.SGD","LU2237443465.HKD","LU1430594728.SGD","LU0234572021.USD","IE000WAW04H5.SGD","LU2087621335.USD","LU0868494617.USD","IE00B19Z3581.USD","LU2237443549.SGD","SG9999015945.SGD","LU0661504455.SGD","ABBV","BK4139","LU1003077747.HKD","LU0942090050.USD","LU1244550221.USD","LU1670627923.USD","LU0098860793.USD","LU0708994859.HKD","LU1162221912.USD","LU0203347892.USD","LU2129689605.HKD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2645786832","title":"Apogee Therapeutics Is Maintained at Sector Perform by RBC Capital","url":"https://stock-news.laohu8.com/highlight/detail?id=2645786832","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2645786832?lang=en_us&edition=fundamental","pubTime":"2026-06-23 22:38","pubTimestamp":1782225480,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/APGE/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  June 23, 2026 10:38 ET (14:38 GMT)","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","LU0310800379.SGD","BK4207","LU1267930573.SGD","LU0053671581.USD","LU0708994859.HKD","LU0128525929.USD","LU0029864427.USD","APGE"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2645839830","title":"Apogee Therapeutics downgraded to Neutral from Buy at Guggenheim","url":"https://stock-news.laohu8.com/highlight/detail?id=2645839830","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2645839830?lang=en_us&edition=fundamental","pubTime":"2026-06-23 20:26","pubTimestamp":1782217614,"startTime":"0","endTime":"0","summary":"Guggenheim downgraded Apogee Therapeutics (APGE) to Neutral from Buy after the company agreed to be acquired by AbbVie (ABBV) for $135.11 per share...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/apogee-therapeutics-downgraded-to-neutral-from-buy-at-guggenheim-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/apogee-therapeutics-downgraded-to-neutral-from-buy-at-guggenheim-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["APGE"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2645358478","title":"Apogee Therapeutics moved to No Rating at BofA","url":"https://stock-news.laohu8.com/highlight/detail?id=2645358478","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2645358478?lang=en_us&edition=fundamental","pubTime":"2026-06-23 19:29","pubTimestamp":1782214190,"startTime":"0","endTime":"0","summary":"BofA moved to No Rating on Apogee Therapeutics (APGE) after the company agreed to be acquired by AbbVie (ABBV) for $135.11 per share in cash. AbbVi...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/apogee-therapeutics-moved-to-no-rating-at-bofa-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/apogee-therapeutics-moved-to-no-rating-at-bofa-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["APGE"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2645336488","title":"Apogee Therapeutics downgraded to Sector Perform from Outperform at RBC Capital","url":"https://stock-news.laohu8.com/highlight/detail?id=2645336488","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2645336488?lang=en_us&edition=fundamental","pubTime":"2026-06-23 19:07","pubTimestamp":1782212852,"startTime":"0","endTime":"0","summary":"RBC Capital downgraded Apogee Therapeutics (APGE) to Sector Perform from Outperform with a price target of $135, up from $97, after AbbVie announce...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/apogee-therapeutics-downgraded-to-sector-perform-from-outperform-at-rbc-capital-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/apogee-therapeutics-downgraded-to-sector-perform-from-outperform-at-rbc-capital-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["APGE"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2645838731","title":"Apogee Therapeutics, Inc.  : Deutsche Bank Raises Target Price to $135 From $116","url":"https://stock-news.laohu8.com/highlight/detail?id=2645838731","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2645838731?lang=en_us&edition=fundamental","pubTime":"2026-06-23 19:03","pubTimestamp":1782212613,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260623:nAQN2M4R9G:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["LU0053671581.USD","BK4139","APGE"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2645789838","title":"Apogee Therapeutics, Inc.  : Deutsche Bank Cuts to Hold From Buy","url":"https://stock-news.laohu8.com/highlight/detail?id=2645789838","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2645789838?lang=en_us&edition=fundamental","pubTime":"2026-06-23 19:03","pubTimestamp":1782212613,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260623:nAQN2M4R9G:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["LU0053671581.USD","BK4139","APGE"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"websiteUrl":"http://www.apogeetherapeutics.com","stockEarnings":[{"period":"1week","weight":0.0006},{"period":"1month","weight":0.6743},{"period":"3month","weight":0.5742},{"period":"6month","weight":0.752},{"period":"1year","weight":1.9998},{"period":"ytd","weight":0.759}],"compareEarnings":[{"period":"1week","weight":0.0171},{"period":"1month","weight":-0.0168},{"period":"3month","weight":0.1371},{"period":"6month","weight":0.0916},{"period":"1year","weight":0.2074},{"period":"ytd","weight":0.0936}],"compareStock":{"symbol":"SPY","name":"SPDR S&P 500 ETF Trust"},"description":"Apogee Therapeutics, Inc., through its subsidiary, operates as a biotechnology company that develops biologics for the treatment of atopic dermatitis (AD), chronic obstructive pulmonary disease (COPD), and related inflammatory and immunology indications. The company primarily develops APG777, a subcutaneous (SQ) extended half-life monoclonal antibody (mAb) for AD; and APG808, an SQ extended half-life mAb for COPD. Its earlier-stage programs include APG990, an SQ extended half-life mAb for the treatment of AD; and APG222, an extended half-life SQ antibodies for AD. The company was founded in 2022 and is based in Waltham, Massachusetts.","yearOnYearQuotes":[{"month":1,"riseRate":0.333333,"avgChangeRate":-0.006689},{"month":2,"riseRate":0.666667,"avgChangeRate":-0.043968},{"month":3,"riseRate":1,"avgChangeRate":0.433037},{"month":4,"riseRate":0.333333,"avgChangeRate":-0.069219},{"month":5,"riseRate":0,"avgChangeRate":-0.056063},{"month":6,"riseRate":0.666667,"avgChangeRate":0.221133},{"month":7,"riseRate":0.666667,"avgChangeRate":0.039623},{"month":8,"riseRate":0.666667,"avgChangeRate":0.024428},{"month":9,"riseRate":0.666667,"avgChangeRate":0.056277},{"month":10,"riseRate":0.333333,"avgChangeRate":0.038958},{"month":11,"riseRate":0.666667,"avgChangeRate":0.091668},{"month":12,"riseRate":1,"avgChangeRate":0.161393}],"exchange":"NASDAQ","name":"Apogee Therapeutics","nameEN":"Apogee Therapeutics"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"isLaohu8Offline":false,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.44.1","shortVersion":"4.44.1","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Apogee Therapeutics(APGE),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest Apogee Therapeutics(APGE) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"Apogee Therapeutics,APGE,Apogee Therapeutics股票,Apogee Therapeutics股票老虎,Apogee Therapeutics股票老虎国际,Apogee Therapeutics行情,Apogee Therapeutics股票行情,Apogee Therapeutics股价,Apogee Therapeutics股市,Apogee Therapeutics股票价格,Apogee Therapeutics股票交易,Apogee Therapeutics股票购买,Apogee Therapeutics股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Apogee Therapeutics(APGE),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest Apogee Therapeutics(APGE) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}